Van Meerbeeck J P, Fennell D A, De Ruysscher D K. Small-cell lung cancer [J]. Lancet, 2011, 378(9804): 1741-1755.
[2]
Byers L A, Rudin C M. Small cell lung cancer: where do we go from here? [J]. Cancer, 2015, 121(5): 664-672.
[3]
Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database [J]. J Clin Oncol, 2006, 24(28): 4539-4544.
[4]
Kalemkerian G P, Akerley W, Bogner P, et al. Small cell lung cancer [J]. JNCCN, 2013, 11(1): 78-98.
[5]
Boldrini L, Ursino S, Gisfredi S, et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance [J]. Clin Cancer Res, 2004, 10(12 Pt 1): 4101-4108.
[6]
Riely G J, Yu H A. EGFR: the paradigm of an oncogene-driven lung cancer [J]. Clin Cancer Res, 2015, 21(10): 2221-2216.
[7]
Warshamana-Greene G S, Litz J, Buchdunger E, et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy [J]. Clin Cancer Res, 2005, 11(4):1563-1571.
[8]
Ferte C, Loriot Y, Clemenson C, et al. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy [J]. Mol Cancer Ther, 2013, 12(7): 1213-1222.
[9]
Arcaro A. Targeted therapies for small cell lung cancer: Where do we stand? [J]. Crit Rev Oncol Hemat, 2015,95(2):154-164.
[10]
Peifer M, Fernandez-Cuesta L, Sos M L, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer [J]. Nat Genet, 2012, 44(10): 1104-1110.
[11]
Schultheis A M, Bos M, Schmitz K, et al. Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer [J]. Modern Pathol, 2014, 27(2): 214-221.
[12]
Pardo O E, Latigo J, Jeffery R E, et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo [J]. Cancer Res, 2009, 69(22): 8645-8651.
[13]
Krystal G W, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy [J]. Mol Cancer Ther, 2002, 1(11): 913-922.
[14]
Wojtalla A, Fischer B, Kotelevets N, et al. Targeting the phosphoinositide 3-kinase p110-alpha isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer [J]. Clin Cancer Res, 2013, 19(1): 96-105.
[15]
Walls M, Baxi S M, Mehta P P, et al. Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216 [J]. Clin Cancer Res, 2014, 20(3): 631-643.
[16]
Schmid K, Bago-Horvath Z, Berger W, et al. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer [J]. Brit J Cancer, 2010,103(5):622-628.
[17]
Jiang S X, Sato Y, Kuwao S, et al. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas [J]. J Pathol,1995,177(2):135-138.
[18]
Ikegaki N, Katsumata M, Minna J, et al. Expression of bcl-2 in small cell lung carcinoma cells [J]. Cancer Res,1994,54(1):6-8.
[19]
Kaiser U, Schilli M, Haag U, et al. Expression of bcl-2--protein in small cell lung cancer [J]. Lung Cancer, 1996,15(1):31-40.
[20]
Farmer H, Mccabe N, Lord C J, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J]. Nature, 2005,434(7035):917-921.
[21]
Ready N E, Dudek A Z, Pang H H, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study [J]. J Clin Oncol, 2011,29(33):4436-4441.
[22]
Horn L, Dahlberg S E, Sandler A B, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501 [J]. J Clin Oncol, 2009,27(35):6006-6011.
[23]
Spigel D R, Greco F A, Zubkus J D, et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer [J]. J Thorac Oncol, 2009,4(12):1555-1560.
[24]
Bustamante Alvarez J G, Gonzalez-Cao M, Karachaliou N, et al. Advances in immunotherapy for treatment of lung cancer [J]. Cancer Biol Med, 2015,12(3):209-222.
[25]
Santarpla M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy [J]. Cancer Biol Med, 2015,12(2):74-78.
[26]
Santarpia M, Gonzalez-Cao M, Viteri S, et al. Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role [J]. Transl Lung Cancer Res, 2015,4(6):728-742.
[27]
Ishii H, Azuma K, Kawahara A, et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer [J]. J Thorac Oncol, 2015,10(3):426-430.
[28]
Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial [J]. Ann Oncol, 2013,24(1):75-83.
[29]
Freeman-Keller M, Goldman J, Gray J. Vaccine immunotherapy in lung cancer: Clinical experience and future directions [J]. Pharmacol Therapeut, 2015,153:1-9.
[30]
Antonia S J, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J]. Clin Cancer Res, 2006,12(3 Pt 1):878-887.
[31]
Kanzler H, Barrat F J, Hessel E M, et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists [J]. Nat Med, 2007,13(5):552-559.
2016, Vol. 27 
